Keros Therapeutics Inc (NASDAQ:KROS) currently has a daily average trading volume of 1.12M but it saw 1163621 shares traded in last market. With a market cap of 584.90M USD, the company’s current market price of $14.42 came rising about 0.84 while comparing to the previous closing price of $14.30. In past 52 weeks, the stock remained buoying in the range of price level as high as $72.37 and as low as $9.12. In the recent trading on the day, stock has struck highest price mark of $14.04 while lowest mark touched by it was $14.52.
Taking a look at 20-day trading activity of Keros Therapeutics Inc (KROS) gives us an average price of $11.83, while its current price level is -80.07% below from 52-week high level whereas it is 58.11% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $11.42 while that of 200 days or SMA-200 reads an average of $35.88. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.64% during that period while stretching the period over a month that increases to 6.27%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 71.46 which implies that the stock is in overbought territory.
Wedbush downgraded its recommendation for the stock as a “Neutral” from “Outperform” on January 17, 2025 while assigning a price target of $15. Oppenheimer issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $102 and $63.
Over the week, KROS’s stock price is moving 6.58% up while it is 27.72% when we observe its performance for the past one month. Year-to-date it is -8.91% down and over the past year, the stock is showing a downside performance of -74.15%.
The company is expected to be releasing its next quarterly report on 2025-Feb-25, for which analysts forecasted an EPS of 0.01 while estimate for next year EPS is -3.2. In next quarter, company is expected to be making quarterly sales of $3.01M as analysts are expecting the sales for current fiscal year at $55.08M and seeing the company making $9.6M in sales next year. Moreover, analysts are in estimates of $56.65M for current-quarter revenue.
Currently, Keros Therapeutics Inc’s total number of outstanding shares is 40.55M with 2.42% of that held by the insiders while 117.21% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -31.84% and return on equity (ROE) at -41.46%. Stock’s beta reads 1.27. Stock has a price to book (P/B) ratio of 1.02 while price to sale or P/S ratio amounts to 164.76. Its return on asset (ROA) is -38.01% on average.
